CN110628845B - 蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 - Google Patents
蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 Download PDFInfo
- Publication number
- CN110628845B CN110628845B CN201910995475.1A CN201910995475A CN110628845B CN 110628845 B CN110628845 B CN 110628845B CN 201910995475 A CN201910995475 A CN 201910995475A CN 110628845 B CN110628845 B CN 110628845B
- Authority
- CN
- China
- Prior art keywords
- disaccharide
- oviductus ranae
- glycosaminoglycan
- heparin
- heparinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003101 oviduct Anatomy 0.000 title claims abstract description 94
- 229920002971 Heparan sulfate Polymers 0.000 title claims abstract description 89
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 238000000605 extraction Methods 0.000 title claims description 14
- 238000004458 analytical method Methods 0.000 title description 4
- 229920000669 heparin Polymers 0.000 claims abstract description 80
- 229960002897 heparin Drugs 0.000 claims abstract description 80
- 150000002016 disaccharides Chemical group 0.000 claims abstract description 57
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 28
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108010022901 Heparin Lyase Proteins 0.000 claims abstract description 16
- 108010006406 heparinase II Proteins 0.000 claims abstract description 9
- 108010083213 heparitinsulfate lyase Proteins 0.000 claims abstract description 9
- 102000004142 Trypsin Human genes 0.000 claims abstract description 8
- 108090000631 Trypsin Proteins 0.000 claims abstract description 8
- 238000000502 dialysis Methods 0.000 claims abstract description 8
- 239000012588 trypsin Substances 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000012535 impurity Substances 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- NBKWLFIAMKBLAZ-UHFFFAOYSA-N 2-amino-2h-acridin-1-one Chemical compound C1=CC=C2C=C(C(C(N)C=C3)=O)C3=NC2=C1 NBKWLFIAMKBLAZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 4
- 238000005349 anion exchange Methods 0.000 claims abstract description 3
- 238000002270 exclusion chromatography Methods 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 239000006228 supernatant Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000012071 phase Substances 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 17
- PIGCSKVALLVWKU-UHFFFAOYSA-N 2-Aminoacridone Chemical compound C1=CC=C2C(=O)C3=CC(N)=CC=C3NC2=C1 PIGCSKVALLVWKU-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 101000637792 Homo sapiens Solute carrier family 35 member G5 Proteins 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 102100032019 Solute carrier family 35 member G5 Human genes 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 239000007791 liquid phase Substances 0.000 claims description 7
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 5
- 238000000825 ultraviolet detection Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 238000003696 structure analysis method Methods 0.000 claims description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000005695 Ammonium acetate Substances 0.000 claims description 3
- 229940043376 ammonium acetate Drugs 0.000 claims description 3
- 235000019257 ammonium acetate Nutrition 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000001212 derivatisation Methods 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 238000001215 fluorescent labelling Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 239000012461 cellulose resin Substances 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000004570 mortar (masonry) Substances 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- -1 heparin disaccharide Chemical class 0.000 abstract description 30
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012916 structural analysis Methods 0.000 description 6
- 230000019635 sulfation Effects 0.000 description 6
- 238000005670 sulfation reaction Methods 0.000 description 6
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/067—Preparation by reaction, e.g. derivatising the sample
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供一种蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法。所述方法为先用微量的胰蛋白酶酶解蛤蟆油,再通过DEAE阴离子交换色谱柱除去蛋白等杂质,并经透析、冻干、浓缩得到蛤蟆油糖胺聚糖(OR‑GAG)。糖胺聚糖由重复的二糖单元构成,通过肝素酶Ⅰ、肝素酶Ⅱ、肝素酶Ⅲ特异性酶解OR‑GAG,再利用分子排阻色谱法,得到硫酸乙酰肝素二糖/肝素二糖(HS/HP二糖)。HS/HP二糖经2‑氨基吖啶酮(AMAC)荧光标记后,利用反相色谱柱C18柱进行质谱分析,得到蛤蟆油中各二糖组分的结构与摩尔百分比。最后,建立HS/HP区域结构模型。
Description
技术领域
本发明是关于蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析,属于天然产物制备纯化领域。
背景技术
蛤蟆油为雌蛙输卵管干制品,呈不规则块状,以白色和黄白色为佳。蛤蟆油中约有50%粗蛋白、30%无氮浸出物、10%灰分、5%脂肪以及2%水分。清朝时期,蛤蟆油便已作为“八珍之首”的上等贡品敬献宫廷,其营养成分不亚于人参、燕窝等补品。蛤蟆油素有“补肾益精,养阴润肺”之功效,现代医学又发现,其具有增强机体免疫力、提高抗氧化能力、降血脂、抗癌辅助作用等。其中,降血脂之功效或与其含有硫酸乙酰肝素与肝素有关。
硫酸乙酰肝素(HS)和肝素(HP)为糖胺聚糖(GAG)的一大分支,是由重复的二糖单元构成的聚阴离子线性长链。其中的二糖单元是由己糖醛酸(HexA)与葡萄糖胺(GlcN)以1-4糖苷键连接而成,HexA有两种结构,分别为葡萄糖醛酸(GlcA)和艾杜糖醛酸(IdoA)。二糖单元通常会有不同程度的硫酸化和乙酰化修饰,主要的修饰位点有HexA的C2位O硫酸化,GlcN的N位硫酸化和N位乙酰化,C6位O硫酸化,一些稀有结构会出现C3位O硫酸化。不同程度的硫酸化修饰影响HS/HP的生物功能,目前发现,HS/HP在细胞发育、血管生成、血液凝固、细胞黏附以及肿瘤代谢方面发挥着重要的作用。
由于国内外未见报道有关蛤蟆油中HS/HP的提取与结构分析, 本发明开创性的建立了一种提取蛤蟆油中HS/HP的方法,并首次对蛤蟆油中的HS/HP进行结构解析,为深入研究蛤蟆油中HS/HP的结构及其功效提供了原创性的提取途径和结构分析手段。
发明内容
本发明的目的在于提供一种蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法。该方法以蛤蟆油为原料,经蛋白酶酶解、离心、DEAE分段洗脱提取得到糖胺聚糖(GAG)。然后,利用透析和冻干的方法除去盐和水,得到纯净的GAG。再分别用肝素酶Ⅰ、肝素酶Ⅱ、肝素酶Ⅲ特异性酶解HS/HP至二糖单元,并通过分子排阻色谱柱S75柱对HS/HP二糖进行纯化,纯化后的二糖利用高温挥发除去流动相中的NH4HCO3,再用荧光物质AMAC(2-氨基吖啶酮)标记,利用ODS色谱柱对HS/HP二糖单元进行质谱结构分析,并根据HS/HP二糖组分的摩尔百分比建立HS/HP区域结构模型。
为实现上述目的,本发明采用如下技术方案:
蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,包括以下步骤:
(1)蛋白酶酶解蛤蟆油:粉末状蛤蟆油充分浸泡后用胰蛋白酶酶解,酶解后离心取上清液。
(2)提取蛤蟆油中的糖胺聚糖:利用DEAE纤维素树脂的阴离子交换作用,置换出蛤蟆油上清液中的糖胺聚糖;透析除去蛤蟆油糖胺聚糖中大量的盐,冻干除去水分。
(3)酶解糖胺聚糖获取二糖组分:用肝素酶Ⅰ、Ⅱ、Ⅲ特异性酶解蛤蟆油糖胺聚糖得到蛤蟆油硫酸乙酰肝素/肝素HS/HP二糖。
(4)分子排阻色谱纯化二糖组分:利用液相分子排阻色谱柱S75柱纯化HS/HP二糖。
(5)LC-MS法分析蛤蟆油中HS/HP二糖组分的结构:液相纯化后的二糖经AMAC(2-氨基吖啶酮)和NaBH3CN衍生化处理后,通过质谱分析得到二糖结构及其组分含量,并建立HS/HP区域结构模型。
蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,包括以下具体步骤:
(1) 蛋白酶酶解蛤蟆油:研磨成粉末状的蛤蟆油在充分浸泡后,加入胰蛋白酶酶解,酶解后的蛤蟆油离心取上清液。
(2) 提取蛤蟆油中的糖胺聚糖:将DEAE柱水洗平衡至稳定状态,加入上清液,再加入平衡液除去蛋白质杂质,然后再用不同高盐浓度洗脱液将糖胺聚糖分段洗脱出来。最后将每管收集到的样品进行紫外检测;利用透析将糖胺聚糖中大量的盐除去,随后利用冻干除去水分。
(3) 酶解糖胺聚糖获取二糖组分:利用肝素酶Ⅰ 、肝素酶Ⅱ、肝素酶Ⅲ将糖胺聚糖酶解至HS/HP二糖单元,再用沸水灭活,离心取上清液。
(4) 分子排阻色谱纯化二糖组分: 取步骤(3)中的上清液,通过分子排阻色谱法利用S75柱对样品进行分离、纯化,从而获得纯净的HS/HP二糖组分。
(5) LC-MS法分析蛤蟆油中HS/HP二糖组分的结构:用AMAC(2-氨基吖啶酮)和氰基硼氢化钠对蛤蟆油中HS/HP二糖进行荧光标记,标记后的HS/HP和CS/DS二糖用MS方法进行分析;根据建立好的标准曲线,得到蛤蟆油中HS/HP的组分含量,并建立HS/HP区域结构模型。
进一步的,步骤(1)蛋白酶酶解蛤蟆油具体为:用研钵将蛤蟆油研磨至粉末状,取100-200 mg浸泡在10-50 mL超纯水中,常温放置24-48 h使其充分溶胀;取100 μL 10-30 μg/μL的胰蛋白酶溶液(酶缓冲液为0.2 M NaCl,10-50 mM磷酸缓冲液),分次加入到蛤蟆油样品中,反应温度36-40℃,反应时长24-48 h。酶解结束,10000 rpm离心10-20 min取上清液。
进一步的,步骤(2)提取蛤蟆油中的糖胺聚糖具体为:用足量的超纯水洗去DEAE树脂中的乙醇,取5-20 mL装柱,用十倍柱体积的0.2 M NaCl,10-50 mM磷酸平衡缓冲液平衡DEAE柱,上样,再加入平衡缓冲液除去蛋白杂质,随后利用分段洗脱的方法提取蛤蟆油中的糖胺聚糖,分段洗脱的不同高盐浓度洗脱液分别为0.5 M NaCl,10-50 mM磷酸缓冲液;1.0M NaCl,10-50 mM磷酸缓冲液,以3 mL/管收集各馏分,并进行紫外检测,波长为212 nm;DEAE收集到的馏分用1000-5000 Da的透析膜透析除去洗脱液中的NaCl,每两小时换一次去离子水,透析2-4天,冻干2-4天除去水,得到纯净的蛤蟆油糖胺聚糖(OR-GAG)。
进一步的,步骤(3)酶解糖胺聚糖获取二糖组分具体为:将步骤(2)提取获得的蛤蟆油糖胺聚糖OR-GAG取0.5-1.0 μg,然后加入肝素酶Ⅰ、肝素酶Ⅱ、肝素酶Ⅲ酶液,各10 μL,酶的浓度均为0.1-1.0 mIU/μL;将蛤蟆油糖胺聚糖OR-GAG特异性酶解至HS/HP二糖单元,酶解温度为36-40℃,酶解时长24-48 h,酶解结束后,10000 rpm离心取上清液。
进一步的,步骤(4)分子排阻色谱纯化二糖组分具体为:取步骤(3)中的上清液,以≤200 μL的上样体积过分子排阻色谱柱,HS/HP二糖经S75柱分离纯化,流动相为0.1-0.3 MNH4HCO3,流速0.4 mL/min,HS/HP二糖在38-44 min出峰并进行收集;流动相中的NH4HCO3通过55-65℃挥发除去。
进一步的,步骤(5)LC-MS法分析蛤蟆油中HS/HP二糖组分的结构具体为:步骤(4)纯化后的蛤蟆油HS/HP二糖经AMAC(2-氨基吖啶酮)荧光标记后,以上样量<20 μL过ODS柱,流动相A相为20-80 mM 醋酸铵,pH=5-7,流动相B相为100%甲醇,流速为0.3 mL/ min,CDL为100-200℃,Heat Block为100-200℃,N2流速为1.5 mL/min,检测电压为1.6-1.8 kV。利用标准曲线分析二糖组分,并建立HS/HP区域模型。
本发明的优点在于:本发明以蛤蟆油为原料,经蛋白酶酶解、离心、DEAE分段洗脱提取得到糖胺聚糖(GAG),利用透析和冻干的方法除去盐和水,得到纯净的GAG。再分别用肝素酶Ⅰ、肝素酶Ⅱ、肝素酶Ⅲ特异性酶解HS/HP至二糖单元,并通过分子排阻色谱柱S75柱对HS/HP二糖进行纯化,纯化后的二糖利用高温挥发除去流动相中的NH4HCO3,再用荧光物质AMAC(2-氨基吖啶酮)标记,利用ODS色谱柱对HS/HP二糖单元进行质谱结构分析,并根据HS/HP二糖组分的摩尔百分比建立HS/HP区域结构模型。首次对蛤蟆油中的HS/HP进行结构解析,为深入研究蛤蟆油中HS/HP的结构及其功效提供了原创性的提取途径和结构分析手段。
附图说明
图1蛤蟆油经DEAE柱分段洗脱所获得组分的紫外图:H1所对应的的洗脱液浓度为0.5 M NaCl,H2所对应的的洗脱液浓度为1.0 M NaCl。较粗线代表UV值,较细线代表NaCl的浓度。
图2 S75柱-HPLC法分离与纯化HS/HP二糖组分:HPLC-H1图为H1样品经肝素酶酶解后过S75柱所得到的的色谱图,HPLC-H2图为H2样品经肝素酶酶解后过S75柱所得到的的色谱图,图中的短线表示HS/HP二糖收集时间范围。
图3 HS/HP二糖化学式。
图4 ODS-MS法建立HS/HP二糖标准曲线。
图5蛤蟆油中HS/HP二糖的EIC图:A为8个标准二糖各100 ng的EIC图,B为H1中所含二糖的EIC图,C为H2中所含二糖的EIC图。1为2S6SNS,2为6SNS,3为2SNS,4为NS,5为2S6SNAc,6为6SNAc,7为2SNAc,8为NAc。
图6 蛤蟆油HS/HP区域结构模型图:图中1为高度硫酸化的S区,2为过渡区NA/NS区,3为无硫酸化的NA区。
具体实施方式
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。
实施例1
蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,包括以下具体步骤:
1.蛤蟆油酶解
取0.1 g蛤蟆油充分研磨成粉末状,溶于20 mL水中,常温浸泡24 h。蛤蟆油在24 h浸泡后充分溶胀,此时加入100 μL 10-30 μg/μL的胰蛋白酶溶液(酶缓冲液为0.2 M NaCl,10-50 mM磷酸缓冲液)在37℃水浴中反应48 h。充分酶解后的蛤蟆油样品以10000 rpm转速离心取上清液。
蛤蟆油中糖胺聚糖的提取
取10 mL DEAE纤维素用超纯水水洗除去乙醇保存液,装柱,再用10倍柱体积的平衡液平衡DEAE柱,将酶解好的蛤蟆油取10 mL上样,待样品与DEAE柱充分结合后用平衡液洗脱出蛋白质等电荷密度较低的杂质,随后再用不同盐浓度的洗脱液提取糖胺聚糖,最后将收集到的样品进行紫外检测,波长为212 nm。其中,平衡液为:0.2 M NaCl,10 mM NaH2PO4/Na2HPO4(pH=7.5);DEAE分段洗脱所用到的洗脱液分别为:0.5 M NaCl,10 mM NaH2PO4/Na2HPO4(pH=7.5),收集样品H1;1.0 M NaCl,10 mM NaH2PO4/Na2HPO4(pH=7.5),收集样品H2。紫外图见图1。
DEAE提取糖胺聚糖的具体参数如下:
DEAE柱柱体积:10 mL
上样量: 10 mL
收集:3 mL/管
流动相:不同盐浓度的磷酸缓冲溶液
柱温:室温
检测器:UV检测器
检测波长:212 nm
3.HS/HP二糖的制备与分离
将过完DEAE柱所收集的馏分按不同盐浓度分为两个部分,分别为样品H1和样品H2。H1和H2分别代表盐浓度为0.5 M、1.0 M的洗脱液所洗脱出的组分。将H1和H2先用分子量为3000 Da的透析膜透析三天、每2 h换一次水,随着换水次数的增多,组分中NaCl的含量逐渐减少,最后被完全除去。透析过后的组分进行冻干与浓缩。
浓缩干的H1和H2分别用肝素酶酶解(其中H1为0.275 g蛤蟆油过DEAE柱用0.5 M盐浓度洗脱液洗脱所收集到的组分。H2为0.275g蛤蟆油过DEAE柱用1.0 M盐浓度洗脱液洗脱所收集到的组分),H1和H2分别取0.7 μg、0.8 μg,然后H1和H2分别用肝素酶酶解,所用肝素酶为酶Ⅰ、酶Ⅱ、酶Ⅲ各10μL,酶浓度均为0.2 mIU/μL,酶反应液为0.1 M NaAc,0.1 mM Ca(Ac)2,pH=7.0(醋酸调pH)。反应温度37℃,反应时长24 h。待反应结束后,用100℃沸水灭活5 min,常温下静置一段时间后,10000 rpm离心10 min取上清液,离心后的沉淀中再加入超纯水100 μL,振荡均匀后,再以10000 r离心10 min取上清液,将两次上清液合并后过液相S75柱。H1和H2上样量为50 mg/200 μL。
S75-HPLC方法具体参数如下:
色谱柱:Superdex™ 75 10/300 GL(10 × 300–310 mm)
流速:0.4 mL/min
上样量:200 μL
流动相:0.2 M NH4HCO3
柱温:室温
检测器:UV检测器
检测波长:232 nm
收集时间:38-44 min;
通过上述方法分离HS/HP二糖,得到的液相图见图2。如图2所示,HPLC-H1图为H1样品经肝素酶酶解后过S75柱所得到的的色谱图,选择保留时间在38-44 min的组分进行收集,得到纯化后的二糖。HPLC-H2图为H2样品经肝素酶酶解后过S75柱所得到的的色谱图,选择保留时间在38-44 min的组分进行收集,得到纯化后的二糖。
实施例 2
1. ODS-MS法建立HS/HP二糖标准曲线
取浓度均为0.1 μg/uL的8种标准二糖各20 μL,均匀混合后浓缩至无水状态。然后,加入5 μL 0.1 M AMAC(AMAC为2-氨基吖啶酮,溶解于乙酸:二甲亚砜=3:17的溶液中),室温下涡旋振荡20 min。随后,加入5 μL 1.0 M 氰基硼氢化钠(NaBH3CN溶解于超纯水中),水浴45℃,反应4 h。整个反应过程中样品需用锡纸包裹达到避光的目的。待反应结束后,用50%二甲亚砜将样品浓度稀释至100ng/10μL、70ng/10μL、60ng/10μL、30ng/10μL以及20ng/10μL进行质谱分析,以样品浓度为横坐标,以峰面积为纵坐标绘制标准曲线。8种标准二糖的结构见图3、m/z值见表一。
表一 8种HS/HP标准二糖结构与m/z值
ODS-MS方法具体参数如下:
色谱柱:ODS-2 HYPERSIL(4.6×250 mm,5 μm)
流速:0.3 mL/min
上样量:10 ul
流动相: A相为40 mM 醋酸铵,pH=5.6;B相为100%甲醇
柱温:45℃
CDL和Heat Block温度:150℃
Nebulizing Gas:1.5 mL/min
检测电压:1.8 kV
线性梯度:0~70 min(15%B~60%B),70~75 min(60%B~100%B)
通过上述方法得到的标准曲线见图4。
分析蛤蟆油HS/HP二糖结构
经液相S75柱纯化后的H1和H2组分,55℃挥发碳酸氢铵3天。然后,浓缩至无水状态并进行衍生化处理,先加入5 μL 0.1 M AMAC在室温下涡旋振荡20 min,再加入5 μL 1.0 M氰基硼氢化钠于45℃水浴中反应4 h。整个反应需注意避光。待反应结束后,用50%二甲亚砜将样品浓度稀释至20 μL,最后用ODS-MS方法分析蛤蟆油中HS/HP二糖结构,得到的质谱图见图5,组分含量见表二。如图5所示,图5中A为8个标准二糖各100 ng的EIC图,B为H1中所含二糖的EIC图,C为H2中所含二糖的EIC图。1为2S6SNS,2为6SNS,3为2SNS,4为NS,5为2S6SNAc,6为6SNAc,7为2SNAc,8为NAc。由表二可知,蛤蟆油中HS/HP二糖组分摩尔百分和含量。HS/HP二糖摩尔百分比最高的为NAc,最低的为6SNS。H1样品中HS/HP二糖总含量为2558.2 ng/g,H2样品中HS/HP二糖总含量为2918.3 ng/g。
表二 蛤蟆油中HS/HP二糖组分摩尔百分和含量
3. 模拟蛤蟆油中HS/HP区域结构模型
在HS长链中各二糖组分有序排列在三种类型的区域结构中,分别为高度硫酸化的S区,过渡的NA/NS区以及无硫酸化的NA区,基于蛤蟆油H1、H2中二糖组分的摩尔百分百,模拟HS/HP区域结构模型。HS/HP区域结构模型见图6。如图6中所示,蛤蟆油无硫酸化的NA区占比最大,其次为过渡区NA/NS区,占比最小为高度硫酸化的S区。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (5)
1.蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,其特征在于,包括以下步骤:
蛋白酶酶解蛤蟆油:粉末状蛤蟆油充分浸泡后用胰蛋白酶酶解,酶解后离心取上清液;
提取蛤蟆油中的糖胺聚糖:利用DEAE纤维素树脂的阴离子交换作用,置换出蛤蟆油上清液中的糖胺聚糖;透析除去蛤蟆油糖胺聚糖中大量的盐,冻干除去水分;
酶解糖胺聚糖获取二糖组分:用肝素酶Ⅰ、Ⅱ、Ⅲ特异性酶解蛤蟆油糖胺聚糖得到蛤蟆油硫酸乙酰肝素/肝素HS/HP二糖;
分子排阻色谱纯化二糖组分:利用液相分子排阻色谱柱S75柱纯化HS/HP二糖;
LC-MS法分析蛤蟆油中HS/HP二糖组分的结构:液相纯化后得到的二糖经2-氨基吖啶酮和氰基硼氢化钠衍生化处理后,通过质谱分析得到二糖结构及其组分含量,并建立HS/HP区域结构模型;
包括以下具体步骤:
(1) 蛋白酶酶解蛤蟆油:研磨成粉末状的蛤蟆油在充分浸泡后,加入胰蛋白酶酶解,酶解后的蛤蟆油离心取上清液;
(2) 提取蛤蟆油中的糖胺聚糖:将DEAE柱水洗平衡至稳定状态,加入上清液,再加入平衡液除去蛋白质杂质,然后再用不同高盐浓度洗脱液将糖胺聚糖分段洗脱出来;最后将每管收集到的样品进行紫外检测;利用透析将糖胺聚糖中大量的盐除去,随后利用冻干除去大部分的水;
(3) 酶解糖胺聚糖获取二糖组分:利用肝素酶Ⅰ 、肝素酶Ⅱ、肝素酶Ⅲ将糖胺聚糖酶解至HS/HP二糖单元,再用沸水灭活,离心取上清液;
(4) 分子排阻色谱纯化二糖组分: 取步骤(3)中的上清液,通过分子排阻色谱法利用S75柱对样品进行分离、纯化,从而获得纯净的HS/HP二糖组分;
(5) LC-MS法分析蛤蟆油中HS/HP二糖组分的结构:用2-氨基吖啶酮AMAC和氰基硼氢化钠对蛤蟆油中HS/HP二糖进行荧光标记,标记后的HS/HP和CS/DS二糖用MS方法进行分析;根据建立好的标准曲线,得到蛤蟆油中HS/HP的组分含量,并建立HS/HP区域结构模型;
步骤(1)蛋白酶酶解蛤蟆油具体为:用研钵将蛤蟆油研磨至粉末状,取100-200 mg浸泡在10-50 mL超纯水中,常温放置24-48 h使其充分溶胀;取100 μL 10-30 μg/μL的胰蛋白酶溶液,加入到蛤蟆油样品中,反应温度36-40℃,反应时长24-48 h,酶解结束,10000 rpm离心10-20 min取上清液。
2.根据权利要求1所述的蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,其特征在于,步骤(2)提取蛤蟆油中的糖胺聚糖具体为:用足量的超纯水洗去DEAE树脂中的乙醇,取5-20 mL装柱,用十倍柱体积的0.2 M NaCl,10-50 mM磷酸平衡缓冲液平衡DEAE柱,上样,再加入平衡缓冲液除去蛋白杂质,随后利用分段洗脱的方法提取蛤蟆油中的糖胺聚糖,分段洗脱的高盐浓度洗脱液分别为0.5 M NaCl,10-50 mM磷酸缓冲液;1.0 M NaCl,10-50 mM磷酸缓冲液,以3 mL/管收集各馏分,并进行紫外检测,波长为212 nm;DEAE收集到的馏分用1000-5000 Da的透析膜透析除去洗脱液中的NaCl,每两小时换一次去离子水,透析2-4天,冻干2-4天除去水,得到纯净的蛤蟆油糖胺聚糖OR-GAG。
3.根据权利要求1所述的蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,其特征在于,步骤(3)酶解糖胺聚糖获取二糖组分具体为:取步骤(2)提取获得的蛤蟆油糖胺聚糖OR-GAG取0.5-1.0 μg, 然后加入肝素酶Ⅰ、肝素酶Ⅱ、肝素酶Ⅲ酶液,各10 μL,酶的浓度均为0.1-1.0 mIU/μL;将蛤蟆油糖胺聚糖OR-GAG特异性酶解至HS/HP二糖单元,酶解温度为36-40℃,酶解时长24-48 h,酶解结束后,10000 rpm离心取上清液。
4.根据权利要求1所述的蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,其特征在于,步骤(4)分子排阻色谱纯化二糖组分具体为:取步骤(3)中的上清液,以≤200 μL的上样体积过分子排阻色谱柱,HS/HP二糖经S75柱分离纯化,流动相为0.1-0.3 M NH4HCO3,流速0.4 mL/min,HS/HP二糖在38-44 min出峰并进行收集;流动相中的NH4HCO3通过55-65℃挥发除去。
5.根据权利要求1所述的蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析方法,其特征在于,步骤(5)LC-MS法分析蛤蟆油中HS/HP二糖组分的结构具体为:步骤(4)纯化后的蛤蟆油HS/HP二糖经2-氨基吖啶酮荧光标记后,以上样量<20 μL过ODS柱,流动相A相为20-80 mM醋酸铵,pH=5-7,流动相B相为100%甲醇,流速为0.3 mL/ min,CDL为100-200℃,Heat Block为100-200℃,N2流速为1.5 mL/min,检测电压为1.6-1.8 kV;利用标准曲线分析二糖组分,并建立HS/HP区域模型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910995475.1A CN110628845B (zh) | 2019-10-18 | 2019-10-18 | 蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910995475.1A CN110628845B (zh) | 2019-10-18 | 2019-10-18 | 蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110628845A CN110628845A (zh) | 2019-12-31 |
CN110628845B true CN110628845B (zh) | 2021-12-21 |
Family
ID=68976811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910995475.1A Expired - Fee Related CN110628845B (zh) | 2019-10-18 | 2019-10-18 | 蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110628845B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111548429B (zh) * | 2020-05-26 | 2021-10-19 | 常熟理工学院 | 一种林蛙油多糖组分及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1287837A (zh) * | 1999-09-14 | 2001-03-21 | 吉林省威特生物应用技术研究所 | 林蛙卵及其应用 |
WO2004045635A1 (ja) * | 2002-11-20 | 2004-06-03 | Otsuka Pharmaceutical Co., Ltd. | 筋肉増加用製剤 |
CN106831896A (zh) * | 2016-12-26 | 2017-06-13 | 大连工业大学 | 含糖醛酸二糖基于还原胺衍生化的分析方法及制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767420B2 (en) * | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
CN102286448B (zh) * | 2011-08-22 | 2013-02-27 | 深圳市海普瑞药业股份有限公司 | 一种肝素黄杆菌肝素酶i、iii的制备方法 |
CN103713057B (zh) * | 2013-12-12 | 2015-07-08 | 中国海洋大学 | 一种降解硫酸乙酰肝素及检测其二糖组成的方法 |
CN106715443A (zh) * | 2014-03-26 | 2017-05-24 | 坎格特生物技术制药有限责任公司 | Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途 |
CN103876146A (zh) * | 2014-04-01 | 2014-06-25 | 吉林大学 | 一种林蛙油多肽含片及其制备方法 |
CN105821097A (zh) * | 2016-04-26 | 2016-08-03 | 刘长国 | 硫酸软骨素/硫酸皮肤素提取方法 |
-
2019
- 2019-10-18 CN CN201910995475.1A patent/CN110628845B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1287837A (zh) * | 1999-09-14 | 2001-03-21 | 吉林省威特生物应用技术研究所 | 林蛙卵及其应用 |
WO2004045635A1 (ja) * | 2002-11-20 | 2004-06-03 | Otsuka Pharmaceutical Co., Ltd. | 筋肉増加用製剤 |
CN106831896A (zh) * | 2016-12-26 | 2017-06-13 | 大连工业大学 | 含糖醛酸二糖基于还原胺衍生化的分析方法及制备方法 |
Non-Patent Citations (2)
Title |
---|
Analysis of Heparan sulfate/heparin from Colla corii asini by liquid chromatography-electrospray ion trap mass spectrometry;Jiayan Du 等;《Glycoconjugate Journal》;20190423;第36卷;第212页右栏第4-5段 * |
正交试验法筛选蛤蟆油粗多糖酶解提取工艺的研究;杨靖 等;《吉林农业大学学报》;20110608;第33卷(第4期);第403-407页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110628845A (zh) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Horner | Macromolecular heparin from rat skin: isolation, characterization, and depolymerization with ascorbate | |
Partridge et al. | The chemistry of connective tissues. 4. The presence of a non-collagenous protein in cartilage | |
JP7250362B2 (ja) | チュウゴクオオサンショウウオ軟骨製剤 | |
Galeotti et al. | Novel reverse-phase ion pair-high performance liquid chromatography separation of heparin, heparan sulfate and low molecular weight-heparins disaccharides and oligosaccharides | |
CN110357983B (zh) | 一种海参岩藻聚糖硫酸酯和硫酸软骨素低聚糖的制备方法 | |
CN101885782B (zh) | 一种从肝素副产物纯化硫酸皮肤素的方法 | |
Stortz et al. | The systems of carrageenans from cystocarpic and tetrasporic stages from Iridaea undulosa: fractionation with potassium chloride and methylation analysis of the fractions | |
CN108530561A (zh) | 一种从肝素生产废弃物中提取高纯硫酸乙酰肝素的方法 | |
CN110628845B (zh) | 蛤蟆油中硫酸乙酰肝素/肝素的提取与结构分析 | |
CN110642962B (zh) | 一种杂豆类果胶多糖的分离纯化方法 | |
Sakugawa et al. | Isolation and chemical characterization of dissolved and particulate polysaccharides in Mikawa Bay | |
Blake et al. | Isolation of fully deuterated metabolites from Scenedesmus obliquus grown in deuterium oxide | |
CN115028750A (zh) | 泡叶藻岩藻多糖及其制备方法和应用 | |
CN110592165B (zh) | 燕窝中硫酸乙酰肝素/肝素的提取方法与结构解析 | |
CN104764847B (zh) | 含n-乙酰化结构肝素寡糖的制备方法 | |
CN110642963A (zh) | 一种提取阿胶中硫酸软骨素/硫酸皮肤素/透明质酸的方法 | |
Barton-Willis et al. | Purification and composition of lipopolysaccharides from Pseudomonas syringae pv. glycinea | |
CN106967186B (zh) | 一种从鱼鳔中提取类肝素化合物的方法 | |
EP0475383A2 (en) | Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient | |
CN104817646B (zh) | 薄树芝中的多糖及其提取方法和应用 | |
CN104004109B (zh) | 海洋硫酸酯化糖胺聚糖se-3及其制备方法 | |
CN110669152B (zh) | 一种从蛤蟆油中提取硫酸软骨素/硫酸皮肤素/透明质酸的方法 | |
CN113880963B (zh) | 一种桑黄多糖及其制备方法和应用 | |
CN113912745A (zh) | 一种糖胺聚糖的分离纯化方法及硫酸化寡糖的制备方法 | |
Uchiyama et al. | Preparation of biologically active fluorescent heparin composed of fluorescein-labeled species and its behavior to antithrombin III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211221 |